Please use this identifier to cite or link to this item: http://hdl.handle.net/10668/678
Title: Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: a preliminary report
Authors: Valdivielso Felices, Pedro
Rioja, José
García-Arias, Carlota
Sánchez-Chaparro, Miguel Ángel
González-Santos, Pedro
metadata.dc.contributor.authoraffiliation: [Valdivielso Felices,P; García-Arias,C; Sánchez-Chaparro,MA; González Santos,P] Lipids Unit, Department of Medicine, Hospital Virgen de la Victoria, Malaga and Department of Medicine & Dermatology, University of Malaga, Malaga, Spain. [Rioja,J] Department of Medicine & Dermatology, University of Málaga, Málaga, Spain.
Keywords: Glucemia;Omacor;Eicosapentaenoic Acid;Docosahexaenoic Acids;Fluvastatin;Apolipoproteína B-48;Presión Arterial;Terapia Combinada;Diabetes Mellitus Tipo 2;Dietoterapia;Ácidos Docosahexaenoicos;Combinación de Medicamentos;Ácido Eicosapentaenoico;Ácidos Grasos Monoinsaturados;Hemoglobina A Glucosilada;Hiperlipidemia Familiar Combinada;Hipertensión;Antihipertensivos;Lípidos;Hipolipemiantes
metadata.dc.subject.mesh: Medical Subject Headings::Chemicals and Drugs::Lipids::Lipoproteins::Apolipoproteins::Apolipoproteins B::Apolipoprotein B-48
Medical Subject Headings::Chemicals and Drugs::Carbohydrates::Monosaccharides::Hexoses::Glucose::Blood Glucose
Medical Subject Headings::Phenomena and Processes::Circulatory and Respiratory Physiological Phenomena::Cardiovascular Physiological Phenomena::Hemodynamics::Blood Pressure
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Combined Modality Therapy
Medical Subject Headings::Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus::Diabetes Mellitus, Type 2
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Nutrition Therapy::Diet Therapy
Medical Subject Headings::Chemicals and Drugs::Lipids::Fats::Dietary Fats::Dietary Fats, Unsaturated::Fatty Acids, Omega-3::Docosahexaenoic Acids
Medical Subject Headings::Chemicals and Drugs::Pharmaceutical Preparations::Drug Combinations
Medical Subject Headings::Chemicals and Drugs::Lipids::Fats::Dietary Fats::Dietary Fats, Unsaturated::Fatty Acids, Omega-3::Eicosapentaenoic Acid
Medical Subject Headings::Chemicals and Drugs::Lipids::Fatty Acids::Fatty Acids, Unsaturated::Fatty Acids, Monounsaturated
Medical Subject Headings::Check Tags::Female
Medical Subject Headings::Chemicals and Drugs::Carbohydrates::Glycosides::Hemoglobin A, Glycosylated
Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
Medical Subject Headings::Diseases::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Metabolism, Inborn Errors::Lipid Metabolism, Inborn Errors::Hyperlipidemia, Familial Combined
Medical Subject Headings::Diseases::Cardiovascular Diseases::Vascular Diseases::Hypertension
Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Hypoglycemic Agents
Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Antimetabolites::Hypolipidemic Agents
Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 2-Ring::Indoles
Medical Subject Headings::Chemicals and Drugs::Lipids
Medical Subject Headings::Check Tags::Male
Medical Subject Headings::Named Groups::Persons::Age Groups::Adult::Middle Aged
Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Cardiovascular Agents::Antihypertensive Agents
Issue Date: 8-Jan-2009
Publisher: BIOMED CENTRAL
Citation: Valdivielso P, Rioja J, García-Arias C, Sánchez-Chaparro MA, González-Santos P. Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: a preliminary report. Cardiovasc Diabetol. 2009;8:1
Abstract: BACKGROUND Mixed hyperlipidemia is common in patients with diabetes. Statins, the choice drugs, are effective at reducing lipoproteins that contain apolipoprotein B100, but they fail to exert good control over intestinal lipoproteins, which have an atherogenic potential. We describe the effect of prescription omega 3 fatty acids on the intestinal lipoproteins in patients with type 2 diabetes who were already receiving fluvastatin 80 mg per day. METHODS Patients with type 2 diabetes and mixed hyperlipidemia were recruited. Fasting lipid profile was taken when patients were treated with diet, diet plus 80 mg of fluvastatin and diet plus fluvastatin 80 mg and 4 g of prescription omega 3 fatty acids. The intestinal lipoproteins were quantified by the fasting concentration of apolipoprotein B48 using a commercial ELISA. RESULTS The addition of 4 g of prescription omega 3 was followed by significant reductions in the levels of triglycerides, VLDL triglycerides and the triglyceride/HDL cholesterol ratio, and an increase in HDL cholesterol (P < 0.05). Fluvastatin induced a reduction of 26% in B100 (P < 0.05) and 14% in B48 (NS). However, the addition of omega 3 fatty acids enhanced this reduction to 32% in B100 (NS) and up to 36% in B48 (P < 0.05). CONCLUSION Our preliminary findings therefore suggest an additional benefit on postprandial atherogenic particles when omega 3 fatty acids are added to standard treatment with fluvastatin.
Description: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't;
URI: http://hdl.handle.net/10668/678
metadata.dc.relation.publisherversion: http://www.cardiab.com/content/8/1/1
metadata.dc.identifier.doi: 10.1186/1475-2840-8-1
ISSN: 1475-2840 (Online)
Appears in Collections:01- Artículos - Hospital Virgen de la Victoria

Files in This Item:
File Description SizeFormat 
Valdivielso_Omega.pdfArtículo publicado323,2 kBAdobe PDFView/Open


This item is protected by original copyright



This item is licensed under a Creative Commons License Creative Commons